CAS 1607837-31-9

CCT-251921

CAS: 1607837-31-9

CCT-251921

Pureza: ≥95%

Peso molecular: 410.9g/mol

Ref: 54-BUP14305

CCT-251921

CAS: 1607837-31-9

CCT-251921 is a molecule that inhibits the activity of cyclin-dependent kinases (CDKs) 4 and 6. It has been shown to inhibit inflammatory bowel disease in animal models, with no observed side effects. The compound also exhibits cytostatic activity against tumor cells by inhibiting β-catenin signaling. CCT-251921 has been shown to have no effect on healthy cells, but does cause cell death in cancer cells due to its ability to inhibit the transcriptional regulation of β-catenin. In addition, CCT-251921 has shown anti-inflammatory properties in clinical trials for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Fórmula: C₂₁H₂₃ClN₆O

Pureza: Min. 95%

Peso molecular: 410.9 g/mol

Ref: 3D-HPC83731

CCT-251921

CAS: 1607837-31-9

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).

Fórmula: C₂₁H₂₃ClN₆O

Pureza: 99.07%

Forma y color: Solid

Peso molecular: 410.9

Ref: TM-T14901